

## OSE PHARMA REINFORCES ITS BOARD

### Jean-Patrick Demonsang and Professor Gérard Tobelem will join the board

### Alexis Peyroles named CFO

**Paris, France, November 12<sup>th</sup>, 2013:** OSE Pharma SA, dedicated to severe and orphan lung diseases announces nomination of two new board members with a broad international experience and the recruitment of a CFO coming from the Healthcare industry. These appointments are part of the plan to launch the phase III of its targeted lung cancer immunotherapy product.

The targeted immunotherapy (OSE2101) is developed for patients with advanced lung cancer (Non-Small Cell Lung Cancer –NSCLC) and the phase 3 is in preparation. OSE 2101 is activating the T cytotoxic lymphocytes enabling them to kill the tumor cells expressing the tumor antigens. This major innovative immune therapy is presenting a new hope for cancer patients.

**M. Jean-Patrick Demonsang** will join as a board member of OSE Pharma. Former President of Seventure Partners till February 2013 he successfully oversaw more than 150 companies mainly involved in Information Technologies and Life Sciences. Over the last 25 years, as an entrepreneur, Jean-Patrick founded and managed numerous SMEs' companies as Chairman & CEO. Mr. Demonsang has a Physics diploma and an MBA from HEC.



**Professor Gérard Tobelem** will also become a board member. He is the winner of the 2006 Diderot Innovation Prize. Professor Tobelem held numerous senior positions at the French Ministry of Research and Higher Education and served as Executive chairman of the French national blood transfusion service (Etablissement Français du Sang). He also worked as a consultant for the R&D divisions of multinational pharmaceutical companies for several years. He is currently Non-Executive Chairman of the French company Theradiag. He is former Professor of Hematology at Paris VII University and the former Head of the Hematology Department at Lariboisière Hospital (Paris).

On the operational side, Alexis Peyroles is joining OSE Pharma as CFO. M. Peyroles has more than 15 years of international experience in the Pharma industry, working for Sanofi then Guerbet in Finance department or General management. Mr Alexis Peyroles holds a BA from EDHEC Business School and an Executive MBA from Imperial College of London.



*« OSE Pharma is today at the forefront of the medical breakthroughs in the immune therapy against cancer and its product portfolio is very promising. It is a great opportunity to collaborate to such an innovative project » adds Alexis Peyroles.*

*. « We are delighted to welcome highly talented and experienced people such as Gérard Tobelem and Jean-Patrick Demonsang to our Board. It will allow OSE Pharma to access new scientific and industrial networks and their international experience will be very valuable in the course of the company's developments» states Emile Loria, M.D., Chairman of the Board for OSE Pharma.*

« OSE Pharma has been able to attract very talented and experienced people who will contribute to the company's growth.» comments Dominique Costantini, CEO of OSE Pharma.

## Contacts presse

### **OSE Pharma SA**

Dominique Costantini, CEO

[dominique.costantini@osepharma.com](mailto:dominique.costantini@osepharma.com)

Mob +33 6 13 20 77 49

### **H&B Communication**

Florence Portejoie

+33 1 58 18 32 58 / +33 6 88 84 81 74

[f.portejoie@hbcommunication.fr](mailto:f.portejoie@hbcommunication.fr)

Anne Hardy

+33 1 58 18 32 51 / +33 6 13 56 23 96

[a.hardy@hbcommunication.fr](mailto:a.hardy@hbcommunication.fr)

---

**COMPANY PROFILE:** Orphan synergy Europe, OSE Pharma, an innovative clinical late stage (Phase III status) biopharmaceutical company established in Paris Hospital Cochin France. The company was founded in 2012 by Emile Loria and Dominique Costantini both experienced Biotech entrepreneurs. OSE Pharma has in-licensed its targeted cancer immunotherapy product OSE2101 for the management of international development and has retained European commercial rights. The company is focused on targeting severe and orphan pulmonary diseases. This medico-economic model is based on protection and acceleration of development for drugs significantly improving treatment options for patients with unmet medical needs. OSE lead product OSE2101 has completed a Phase II clinical trial in late-stage non-small cell lung cancer HLA A2 positive patients. This HLA A2 biomarker is expressed in 45% of this population and is considered as a poor prognosis factor in various cancers including the NSCLC. The 10 epitopes combined are providing T cytotoxic responses (able to kill cells) of the tumor cells expressing the tumor antigens. The 5 Tumor associated antigens targeted - TAA (HER2/neu; P53; CEA; MAGE2; MAGE3) have been selected as their presence is linked to the poor prognosis and severity of various cancers. Two clinical phase I/II results in colon cancer and in NSCLC were performed to define the tolerance, the level of response (>90%) and the scheme of administration (subcutaneous injection every 3 weeks for 6 injections then every 3 months).

OSE 2101 cancer immune therapy could potentially be applied to other cancer indications.

The company is preparing a separate clinical project in Cystic Fibrosis, an orphan genetic disorder with progressive lung damage, reprofiling a molecule with new anti-inflammatory properties. This molecule safety profile is already established allowing the immediate design of a clinical phase II Proof of concept program.